Change in White Cell Count during Treatment of Advanced Cancer of the Prostate with Estramustine Phosphate and with Stilboestrol

D'Aponte, D; Sylvester, R.; Pauw, M. De; Fryszman, A.; Smith, R. M.; Smith, Philip H.

doi:10.1111/j.1464-410x.1983.tb03333.x

Cited by 9 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For another, chemotherapy combined with estramustine showed a significantly low incidence of neutropenia, because treatment with estramustine showed that increasing the leukocyte count led to the myeloprotection in patients with hormone-naive PCa or CRPC. [32,33] However, further studies were needed to clarify this point. Therefore, our meta-analysis indicated that the profile of toxicity associated with both between chemotherapy with estramustine and primary chemotherapy was equivalent, all the toxic side-effects were tolerable and manageable.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer

Qin

Zhang

et al. 2016

Medicine

View full text Add to dashboard Cite

Background:Recently, increasing relevant studies researched the efficacy of castration resistant prostate cancer (CRPC) patients using chemotherapy with or without estramustine, in order to assess the efficacy and toxicity of combining estramustine with chemotherapy for the treatment of CRPC.Methods:Relevant randomized clinical trials were systematically searched from the databases Pubmed, Embase, and Web of science up to April 1, 2016. Data were centrally extracted and analyzed from the previous studies by 2 independent reviewers. The primary endpoint was overall survival (OS) with pooled hazard ratios. Secondary endpoints were prostate-specific antigen (PSA) response and grade 3 or 4 toxicity using pooled odds ratios. Stata version 12.0 software was used for statistical analysis.Results:Overall, this meta-analysis identified 9 eligible articles, including a total of 956 patients, who had been accrued between January 1, 1993 and December 1, 2010 and randomly divided into chemotherapy with estramustine and without estramustine. Chemotherapy (with or without estramustine) consisted of docetaxel, paclitaxel, ixabepilone, epirubicin, and vinblastine. Patients who received chemotherapy with estramustine had a better improvement in PSA response rate, comparing those without estramustine (OR = 1.84, 95% CI = 1.20–2.80). However, OS between the 2 groups indicated no significant differences (HR = 0.90, 95% CI = 0.77–1.05). Besides, these results of meta-analysis showed no obvious differences between these 2 groups in grade 3 or 4 adverse effects, including anemia (OR = 0.78, 95% CI = 0.38–1.57), neutropenia (OR = 0.91, 95% CI = 0.59–1.43), thrombocytopenia (OR = 0.68, 95% CI = 0.19–2.42), nausea (OR = 2.34, 95% CI = 0.81–6.72), vomiting (OR = 2.43, 95% CI = 0.69–8.51), diarrhea (OR = 3.45, 95% CI = 0.93–12.76), fatigue (OR = 0.67, 95% CI = 0.32–1.41), neuropathy (OR = 0.54, 95% CI = 0.21–1.44), allergic reaction (OR = 1.60, 95% CI = 0.37–6.84), thromboembolic event (OR = 2.18, 95% CI = 0.86–5.51), and edema (OR = 1.02, 95% CI = 0.18–5.95).Conclusions:This meta-analysis indicated chemotherapy with additional estramustine increased the PSA response rate. However, OS and grade 3 or 4 toxicity were not improved for these patients with CRPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer

Qin

Zhang

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…Meta-analysis [ 3 ] of chemotherapy combined with EMP showed a significantly low incidence of neutropenia due to concomitant use of EMP in the chemothrapy. In addition, treatment with EMP showed increase in the leukocyte count in patients with hormone-naïve prostate cancer [ 21 ] or CRPC [ 22 ]. Taken together, it is suggested that EMP increases the leukocyte count leading to the myeloprotection in the chemotherapy, albeit under limited conditions; hence, the significance of addition of EMP to DTX therapy may be attributed to the myeloprotection rather than the survival benefit.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

et al. 2012

View full text Add to dashboard Cite

BackgroundThe significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the significance of DTX and EMP combination therapy in Japanese EMP-refractory CRPC patients.MethodsTo compare the efficacy and toxicity of DTX and EMP, we divided CRPC patients, who were confirmed to be resistant to EMP, into the following two groups: group D (n = 28), which included patients treated with DTX (60 mg/m2, once in every four weeks) alone, and group DE (n = 33), which included patients treated with a combination of DTX (60 mg/m2, once in every four weeks) and EMP (twice daily oral administration at 280 mg).ResultsProstate specific antigen (PSA) response (> 50% decline in PSA) was observed in six patients (21%) in group D and eight patients (24%) in group DE. The median time to progression (TTP) was 12.0 months and 6.2 months and the median overall survival (OS) was 26.4 months and 24.3 months in group D and DE, respectively. There was no statistical difference between the two groups in terms of PSA response, TTP, and OS. The incidence of adverse events of grade 3/4 was low in both the groups, and there was no statistical difference between the two groups.ConclusionsAlthough treatment with DTX at 60 mg/m2 was effective and highly tolerated in EMP-refractory Japanese CRPC patients, the DTX and EMP combination therapy might not exhibit any survival benefit for CRPC patients.

show abstract

“…This phenomenon was first reported by Daponte et al . in 1983 42 . This physiological response to an anticancer agent is quite unusual; however, it had not previously attracted our attention.…”

Section: Personalized Medication Of Estramustine Phosphate By Individmentioning

confidence: 94%

Hormonal therapy for prostate cancer: Current topics and future perspectives

et al. 2010

View full text Add to dashboard Cite

Change in White Cell Count during Treatment of Advanced Cancer of the Prostate with Estramustine Phosphate and with Stilboestrol

Cited by 9 publications

References 9 publications

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

Hormonal therapy for prostate cancer: Current topics and future perspectives

Contact Info

Product

Resources

About